Storia in 2 fonti

Novartis and Orionis strike second molecular glue deal for $40M upfront

Novartis inks second molecular glue deal with Orionis Biosciences, paying $40M upfront and up to $1.4B in milestones across multiple disease areas.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Novartis inks second molecular glue deal with Orionis Biosciences, paying $40M upfront and up to $1.4B in milestones across multiple disease areas.

Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines